ImmunityBio, Inc. (IBRX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
IBRX Revenue Growth
Revenue Breakdown (FY 2024)
IBRX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
IBRX Revenue Analysis (2013–2024)
As of May 7, 2026, ImmunityBio, Inc. (IBRX) generated trailing twelve-month (TTM) revenue of $82.6 million, reflecting explosive growth of +425.1% year-over-year. The most recent quarter (Q3 2025) recorded $32.1 million in revenue, up 21.3% sequentially.
Looking at the longer-term picture, IBRX's 5-year compound annual growth rate (CAGR) stands at +221.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $14.7 million in 2024, representing a new all-time high.
Revenue diversification analysis shows IBRX's business is primarily driven by Product (96%), and Product and Service, Other (4%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NKTR (-32.8% YoY), FATE (-51.2% YoY), and CRIS (-13.4% YoY), IBRX has outperformed the peer group in terms of revenue growth. Compare IBRX vs NKTR →
IBRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IBRXCurrent | $83M | +425.1% | +221.4% | -2334.2% | |
 NKTR | $55M | -32.8% | -18.4% | -253.7% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 CRIS | $9M | -13.4% | -2.7% | -348.4% | |
 ADCT | $81M | +4.4% | - | -133.2% |
IBRX Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $14.7M | +2270.6% | $14.7M | 100.0% | $-344,182,000 | -2334.2% |
| 2023 | $622K | +159.2% | $622K | 100.0% | $-362,250,000 | -58239.5% |
| 2022 | $240K | -74.3% | $240K | 100.0% | $-351,298,000 | -146374.2% |
| 2021 | $934K | +54.4% | $934K | 100.0% | $-330,280,000 | -35361.9% |
| 2020 | $605K | +1307.0% | $605K | 100.0% | $-220,880,000 | -36509.1% |
| 2019 | $43K | -8.5% | $-8,969,000 | -20858.1% | $-66,907,000 | -155597.7% |
| 2018 | $47K | +4.4% | $3.2M | 6717.0% | $-98,389,000 | -209338.3% |
| 2017 | $45K | +2.3% | $45K | 100.0% | $-99,120,000 | -220266.7% |
| 2016 | $44K | -81.4% | $44K | 100.0% | $-124,500,000 | -282954.5% |
| 2015 | $236K | -63.2% | $236K | 100.0% | $-238,876,000 | -101218.6% |
See IBRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IBRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IBRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIBRX — Frequently Asked Questions
Quick answers to the most common questions about buying IBRX stock.
Is IBRX's revenue growth accelerating or slowing?
IBRX revenue is accelerating at +425.1% year-over-year, exceeding the 5-year CAGR of +221.4%. TTM revenue reached $83M. Growth momentum has increased versus prior periods.
What is IBRX's long-term revenue growth rate?
ImmunityBio, Inc.'s 5-year revenue CAGR of +221.4% reflects the sustained expansion pattern. Current YoY growth of +425.1% is above this long-term average.
How is IBRX's revenue distributed by segment?
IBRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.